Communiqués OncoSec Medical Incorporated

Actions

ONCSQ

US68234L4059

Temps Différé OTC Markets Autres places de cotation 20:15:21 29/05/2024			Varia. 5j.	Varia. 1 janv.
0,0001 ^USD	+9 900,00 %		-.--%	-.--%

2023	Wall Street devrait ouvrir en baisse avant la publication de l'indice flash des directeurs d'achat de juin ; les prix du pétrole chutent fortement	MT
2023	Les contrats à terme américains sont en baisse avant la publication de l'indice composite des directeurs d'achat de juin.	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

OncoSec Medical Incorporated : Bankruptcy - Form 8-K	14/06/23	PU
ONCOSEC MEDICAL INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	02/06/23	AQ
OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	18/05/23	PR
OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	16/05/23	PR
OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program	16/05/23	PR
ONCOSEC MEDICAL INC : Other Events, Financial Statements and Exhibits (form 8-K)	27/04/23	AQ
OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program	27/04/23	PR
ONCOSEC MEDICAL INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)	11/04/23	AQ
OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	11/04/23	PR
OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	10/04/23	PR
OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with KEYTRUDA in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment	04/04/23	AQ
ONCOSEC MEDICAL INC : Other Events, Financial Statements and Exhibits (form 8-K)	03/04/23	AQ
OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment	03/04/23	PR
ONCOSEC MEDICAL INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	14/03/23	AQ
Methes Energies International Ltd ($MEIL) enters into the b2 biOil and bio-lubricant sector via acquisition of EarthFriendly Products Inc	02/03/23	AQ
ONCOSEC MEDICAL INC : Other Events (form 8-K)	22/02/23	AQ
ONCOSEC MEDICAL INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	04/01/23	AQ
ONCOSEC MEDICAL INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	28/12/22	AQ
ONCOSEC MEDICAL INC : Change in Directors or Principal Officers (form 8-K)	27/12/22	AQ
ONCOSEC MEDICAL INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	15/12/22	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués OncoSec Medical Incorporated

Actions

ONCSQ

US68234L4059

Communiqués

Filtres